Latest Conference Coverage

Pitolisant Improves Daytime Sleepiness and Cataplexy in Severely Burdened Patients

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

Marwan Sabbagh, MD: Observations From AAIC 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.

Lemborexant Demonstrates Efficacy in Elders

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

Lemborexant Improves Sleep Outcomes Following Placebo Randomization Switch

Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.

Cognitive Behavioral Therapy for Insomnia Shows Multiple Benefits for Women

Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.

Katrina Celis, MD: Genetics and Their Role in Alzheimer Research, Clinical Care

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed the role that increased APOE ε4 expression can have on future research and clinical care.

Q&A: Genetic Ancestry and Alzheimer Disease Risk

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

Sargramostim Shows Safety and Promise as Potential Alzheimer Treatment

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

Dementia-Related Psychosis Places Heavy Burden on Patients and Caretakers

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

12 Modifiable Risk Factors to Reduce Dementia Risk

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

Nilotinib Safety Profile Sets Agent Up For Phase 3 Study

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

Katrina Celis, MD: Ancestral Genetics and the Impact on Alzheimer Disease Risk

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Hypertension, Diabetes, High BMI All Early Life Risk Factors for Dementia

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

VU319 Shows Safe Profile and Potential as M1 Allosteric Modulator for MCI

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Candesartan Shows Signs of Neuroprotection in Older Adults With MCI and Hypertension

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.

Pimavanserin Reduces Dementia-Related Psychosis Symptoms

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.

Matthew Robbins, MD: Headaches Associated With COVID-19

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.

Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.

Matthew Robbins, MD: Residency During COVID-19

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

Migraine Care During a Pandemic: Takeaways for the Future

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.